Related Experiment Video
Updated: May 22, 2026
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Nanosensing protein allostery using a bivalent mouse double minute two (MDM2) assay
Anna F Robson1, Ted R Hupp, Fiona Lickiss
1Centre for Molecular Nanometrology, WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.
Abstract:
The tumor suppressor protein, p53, is either mutated or absent in >50% of cancers and is negatively regulated by the mouse double minute (MDM2) protein. Understanding and inhibition of the MDM2-p53 interaction are, therefore, critical for developing novel chemotherapeutics, which are currently limited because of a lack of appropriate study tools. We present a nanosensing approach to investigate full-length MDM2 interactions with p53, thus providing an allosteric assay for identifying binding ligands. Surface-enhanced Raman scattering (SERS)-active nanoparticles, functionalized with a p53 peptide mimic (peptide 12.1), display biologically specific aggregation following addition of MDM2. Nanoparticle assembly is competitively inhibited by the N-terminal MDM2-binding ligands peptide 12.1 and Nutlin-3. This study reports nanoparticle assembly through specific protein-peptide interactions that can be followed by SERS. We demonstrate solution-based MDM2 allosteric interaction studies that use the full-length protein.
Insights
Researchers developed a novel nanosensing method to study the MDM2-p53 interaction, crucial for cancer drug development. This assay uses surface-enhanced Raman scattering (SERS) nanoparticles to detect binding, offering a new tool for identifying potential cancer therapeutics.
Area of Science:
- Biochemistry
- Nanotechnology
- Chemical Biology
Background:
- The tumor suppressor protein p53 is critical in cancer, often inactivated by MDM2.
- Targeting the MDM2-p53 interaction is a key strategy for cancer therapy.
- Current tools for studying this interaction are limited, hindering drug discovery.
Purpose of the Study:
- To develop a novel nanosensing assay for investigating the full-length MDM2-p53 interaction.
- To provide an allosteric assay for identifying binding ligands of the MDM2-p53 complex.
- To establish a solution-based method for studying protein-protein interactions using nanoparticles.
Main Methods:
- Utilized surface-enhanced Raman scattering (SERS)-active nanoparticles functionalized with a p53 peptide mimic (peptide 12.1).
- Observed nanoparticle aggregation upon addition of full-length MDM2 protein, indicating specific binding.
- Demonstrated competitive inhibition of nanoparticle assembly by known MDM2-binding ligands (peptide 12.1 and Nutlin-3).
Main Results:
- Successfully developed a SERS-based nanosensing approach to monitor MDM2-p53 interactions in solution.
- Showcased specific, biologically relevant nanoparticle aggregation driven by protein-peptide binding.
- Validated the assay's ability to identify and characterize MDM2-binding ligands.
Conclusions:
- The developed nanosensing assay enables robust investigation of full-length MDM2-p53 interactions.
- This platform serves as a valuable tool for screening and identifying novel therapeutic agents targeting the MDM2-p53 pathway.
- The study demonstrates the potential of SERS-based nanoparticle assembly for studying protein interactions in biochemical research.
More Related Videos
05:54A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
Published on: December 29, 2017
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025